A Randomized, Open Label, Prospective, Parallel Group Study to Assess the Natural History of COVID-19 and Effects of KB109 in Addition to Supportive Self Care (SSC) Compared to SSC Alone on Measures of Health in Non-hospitalized Patients With Mild-Moderate COVID-19
Latest Information Update: 18 Aug 2021
At a glance
- Drugs KB 109 (Primary)
- Indications COVID 2019 infections
- Focus Adverse reactions
- Sponsors Kaleido Biosciences
Most Recent Events
- 12 Aug 2021 Status changed from active, no longer recruiting to completed.
- 24 Jun 2021 Results assessing the safety and physiologic effects of KB109 combined with self-supportive care (SSC) vs SSC alone in non-hospitalized patients with mild to moderate COVID-19 presented at the World Microbe Forum 2021
- 24 Mar 2021 Results (full dataset) presented in a Kaleido Biosciences media release.